Development of a rapid phenotypic test for HCV protease inhibitors with potential use in clinical decisions

Abstract Approximately 185 million people worldwide are chronically infected with hepatitis C virus (HCV). The first-wave of approved NS3 protease inhibitors (PIs) were Telaprevir and Boceprevir, which are currently discontinued. Simeprevir is a second-wave PI incorporated into the Brazilian hepatit...

Descripció completa

Dades bibliogràfiques

Autors principals:	Luciana Santos Pessoa, Luãnna Liebscher Vidal, Emmerson C.B. da Costa, Celina Monteiro Abreu, Rodrigo Delvecchio da Cunha, Ana Luiza Chaves Valadão, André Felipe dos Santos, Amilcar Tanuri
Format:	Artigo
Idioma:	Inglês
Publicat:	Sociedade Brasileira de Genética
Col·lecció:	Genetics and Molecular Biology
Matèries:	protease inhibitor phenotypic test hepatitis C virus HCV NS3 protease resistance mutation
Accés en línia:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1415-47572016000300358&lng=en&tlng=en
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!